Spots Global Cancer Trial Database for lung cancer, small cell
Every month we try and update this database with for lung cancer, small cell cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | NCT00259935 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Regulatory Hycamtin(Oral) PMS | NCT01037023 | Lung Cancer, Sm... | Topotecan | - | GlaxoSmithKline | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | NCT06228326 | Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | NCT00046111 | Lung Cancer, Sm... Solid Tumor Can... | topotecan | 18 Years - | GlaxoSmithKline | |
| Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment | NCT04440800 | Lung Cancer, Sm... Pancreatic Canc... Gastric Cancer Oesophageal Can... Lung Cancer, No... Lung Cancer Met... | Wearable activi... | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | NCT00259935 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | NCT00294931 | Carcinoma, Smal... | irinotecan carboplatin bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| SCOT Registry: Small Cell Lung Cancer Treatment and Outcome | NCT00997061 | Lung Cancer, Sm... | HYCAMTIN | 18 Years - | GlaxoSmithKline | |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC | NCT05228496 | Lung Cancer, Sm... | Tislelizumab Sitravatinib | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan | NCT06293833 | Lung Cancer, No... Lung Cancer Smoking Cessati... Lung Cancer, Sm... | Low-dose CT sca... Smoking Cessati... | 55 Years - 74 Years | University Hospital, Antwerp | |
| Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | NCT03499678 | Lung Cancer Lung Cancer, No... Lung Cancer, Sm... | 18 Years - | HKGepitherapeutics | ||
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan | NCT06293833 | Lung Cancer, No... Lung Cancer Smoking Cessati... Lung Cancer, Sm... | Low-dose CT sca... Smoking Cessati... | 55 Years - 74 Years | University Hospital, Antwerp | |
| NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | NCT04986670 | Lung Cancer, Sm... Lung Cancer Met... Lung Cancer Rec... Treatment Side ... Lung Cancer, No... Nutritional Imb... | Nutritional Cou... Medically Tailo... Nutrition Presc... Nutrition Asses... Nutrition Toolk... Monthly Emails | 18 Years - 100 Years | Tufts University | |
| Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | NCT00276276 | Lung Cancer, Sm... | topotecan | 18 Years - | GlaxoSmithKline | |
| The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) | NCT00043862 | Lung Cancer, Sm... Small Cell Lung... | topotecan | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
